VRTX : Summary for Vertex Pharmaceuticals Incorpor - Yahoo Finance

U.S. Markets open in 3 hrs 47 mins

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
83.17+0.78 (+0.95%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close82.39
Bid80.23 x 200
Ask87.64 x 100
Day's Range81.76 - 84.41
52 Week Range71.46 - 103.73
Avg. Volume2,101,100
Market Cap20.63B
PE Ratio (TTM)-73.34
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Merck KGaA, Vertex Announce Tie-Up for Oncology Programs
    Zacks5 days ago

    Merck KGaA, Vertex Announce Tie-Up for Oncology Programs

    Merck (MKGAF) and Vertex (VRTX) collaborated for the development and commercialization of four research and development programs for the treatment of cancer.

  • Vertex Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VRTX) : January 11, 2017
    Capital Cube6 days ago

    Vertex Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VRTX) : January 11, 2017

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Vertex Pharmaceuticals, Inc. a score of 28. Our analysis is based on comparing Vertex Pharmaceuticals, Inc. with the following peers – Gilead Sciences, Inc., AbbVie, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Enzon Pharmaceuticals, Inc., Enanta Pharmaceuticals, Inc. and SciClone Pharmaceuticals, Inc. (GILD-US, ... Read more (Read more...)

  • American City Business Journals6 days ago

    Vertex deals cancer drug programs to Merck KGaA for $230M

    Vertex Pharmaceuticals said Wednesday that it will license four cancer drug programs to German pharma giant Merck KGaA in exchange for $230 million, plus future royalties. Boston’s Vertex (VRTX), which is best known for its cystic fibrosis drugs, said that two of the cancer programs are in clinical trials, while the other two are in the preclinical stage. Merck, a multinational company that goes by the full name Merck KGaA, Darmstadt, Germany, will fully assume responsibility for developing and commercializing the drugs, while Vertex will receive royalties on future sales.